Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial
Abstract Background Despite World Health Organization recommendations, in many countries young children are not targeted for influenza vaccination. To help inform influenza vaccination policy, we examined the occurrence and burden of influenza in healthy children aged 6 to 35 months using data from...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-04-01
|
Series: | BMC Infectious Diseases |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12879-019-3920-8 |
id |
doaj-ed68e6655d374922b6e05ca7e914f827 |
---|---|
record_format |
Article |
spelling |
doaj-ed68e6655d374922b6e05ca7e914f8272020-11-25T03:47:13ZengBMCBMC Infectious Diseases1471-23342019-04-011911610.1186/s12879-019-3920-8Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trialClotilde El Guerche-Séblain0Annick Moureau1Camille Schiffler2Martin Dupuy3Stephanie Pepin4Sandrine I. Samson5Philippe Vanhems6François Schellevis7Global Vaccine and Epidemiology Department, Sanofi PasteurGlobal Clinical Biostatistics Department, Sanofi PasteurGlobal HEOR Department, Sanofi PasteurGlobal Biostatistics Department, Sanofi PasteurGlobal Clinical Sciences, Sanofi PasteurGlobal Medical Affairs, Sanofi PasteurEpidemiology and International Health Team, Emergent Pathogens Laboratory, Fondation Mérieux, International Center for Research in Infectiology, National Institute of Health and Medical Research, U1111, National Center of Scientific Research, Mixed Scientific Unit 5308, École Nationale Supérieure de Lyon, Université Claude Bernard Lyon 1Netherlands Institute for Health Services ResearchAbstract Background Despite World Health Organization recommendations, in many countries young children are not targeted for influenza vaccination. To help inform influenza vaccination policy, we examined the occurrence and burden of influenza in healthy children aged 6 to 35 months using data from a recent phase III placebo-controlled influenza vaccine trial conducted in countries in the Northern and Southern Hemispheres. Methods This was an analysis of data from participants included in the placebo arm of a phase III clinical trial in healthy children aged 6 to 35 months (EudraCT no. 2013–001231-51). Included children had never been vaccinated for influenza and were observed for one influenza season. Outcome measures included the occurrence of influenza-like illness (ILI), laboratory-confirmed influenza, virus types/subtypes, severe symptoms and complications of confirmed influenza, and healthcare use associated with confirmed influenza. Results Data from 2210 participants were analysed. ILI was reported for 811 participants (36.7%). Of these, 255 participants (31.4%) had 263 virologically confirmed episodes of influenza. The overall influenza attack rate was 11.5%. The most common influenza virus detected was A(H3N2) (40.7%), followed by B/Yamagata (23.6%), A(H1N1) (18.6%), and B/Victoria (8.0%). Grade 3 fever was reported in 24.3% of confirmed episodes, acute lower respiratory infection in 8.7%, acute otitis media in 6.1%, and pneumonia in 1.9%. In most influenza episodes (93.2%), antipyretics, analgesics, or non-steroidal anti-inflammatory drugs were taken. Antibiotics were prescribed for 41.4% of influenza episodes. More than half of the influenza episodes (57.0%) resulted in outpatient visits. Influenza resulted in overnight hospitalisation in 1.1% of episodes. Conclusions Influenza is associated with a significant burden of disease in healthy children. This analysis also revealed that antibiotics continue to be frequently used for young children with influenza. Trial registration EudraCT no. 2013–001231-51.http://link.springer.com/article/10.1186/s12879-019-3920-8InfluenzaChildrenFeverHospitalisationEpidemiologyClinical trial |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Clotilde El Guerche-Séblain Annick Moureau Camille Schiffler Martin Dupuy Stephanie Pepin Sandrine I. Samson Philippe Vanhems François Schellevis |
spellingShingle |
Clotilde El Guerche-Séblain Annick Moureau Camille Schiffler Martin Dupuy Stephanie Pepin Sandrine I. Samson Philippe Vanhems François Schellevis Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial BMC Infectious Diseases Influenza Children Fever Hospitalisation Epidemiology Clinical trial |
author_facet |
Clotilde El Guerche-Séblain Annick Moureau Camille Schiffler Martin Dupuy Stephanie Pepin Sandrine I. Samson Philippe Vanhems François Schellevis |
author_sort |
Clotilde El Guerche-Séblain |
title |
Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial |
title_short |
Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial |
title_full |
Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial |
title_fullStr |
Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial |
title_full_unstemmed |
Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial |
title_sort |
epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase iii efficacy trial |
publisher |
BMC |
series |
BMC Infectious Diseases |
issn |
1471-2334 |
publishDate |
2019-04-01 |
description |
Abstract Background Despite World Health Organization recommendations, in many countries young children are not targeted for influenza vaccination. To help inform influenza vaccination policy, we examined the occurrence and burden of influenza in healthy children aged 6 to 35 months using data from a recent phase III placebo-controlled influenza vaccine trial conducted in countries in the Northern and Southern Hemispheres. Methods This was an analysis of data from participants included in the placebo arm of a phase III clinical trial in healthy children aged 6 to 35 months (EudraCT no. 2013–001231-51). Included children had never been vaccinated for influenza and were observed for one influenza season. Outcome measures included the occurrence of influenza-like illness (ILI), laboratory-confirmed influenza, virus types/subtypes, severe symptoms and complications of confirmed influenza, and healthcare use associated with confirmed influenza. Results Data from 2210 participants were analysed. ILI was reported for 811 participants (36.7%). Of these, 255 participants (31.4%) had 263 virologically confirmed episodes of influenza. The overall influenza attack rate was 11.5%. The most common influenza virus detected was A(H3N2) (40.7%), followed by B/Yamagata (23.6%), A(H1N1) (18.6%), and B/Victoria (8.0%). Grade 3 fever was reported in 24.3% of confirmed episodes, acute lower respiratory infection in 8.7%, acute otitis media in 6.1%, and pneumonia in 1.9%. In most influenza episodes (93.2%), antipyretics, analgesics, or non-steroidal anti-inflammatory drugs were taken. Antibiotics were prescribed for 41.4% of influenza episodes. More than half of the influenza episodes (57.0%) resulted in outpatient visits. Influenza resulted in overnight hospitalisation in 1.1% of episodes. Conclusions Influenza is associated with a significant burden of disease in healthy children. This analysis also revealed that antibiotics continue to be frequently used for young children with influenza. Trial registration EudraCT no. 2013–001231-51. |
topic |
Influenza Children Fever Hospitalisation Epidemiology Clinical trial |
url |
http://link.springer.com/article/10.1186/s12879-019-3920-8 |
work_keys_str_mv |
AT clotildeelguercheseblain epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial AT annickmoureau epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial AT camilleschiffler epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial AT martindupuy epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial AT stephaniepepin epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial AT sandrineisamson epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial AT philippevanhems epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial AT francoisschellevis epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial |
_version_ |
1724502943505317888 |